Vaccinex (VCNX)

• Market cap: $8.69M
• 1 day: -1.58%
• 5 days: -4.60%
• 1 month: 22.92%
• 3 months: -39.38%
• 6 months: -43.45%
• Year to date: -70.52%
• 1 year: -75.59%
• 5 years: -99.68%
• 10 years: -99.87%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Employees: 40

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

9% more funds holding

Funds holding: 11 [Q2] → 12 (+1) [Q3]

1.06% less ownership

Funds ownership: 20.46% [Q2] → 19.39% (-1.06%) [Q3]

37% less capital invested

Capital invested by funds: $1.81M [Q2] → $1.14M (-$674K) [Q3]